orally available E-selectin antagonist
/ GlycoMimetics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 07, 2021
Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study.
(PubMed, Glycobiology)
- "At first, the experimentally confirmed inhibitors were docked into all three selectins' carbohydrate recognition domains to assess the suitability of the screening procedure. Finally, based on the evaluation of ligands binding, we propose ten purchasable pan-selectin inhibitors to develop COVID-19 therapeutics."
Journal • Acute Respiratory Distress Syndrome • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1